PL442000A1 - Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów - Google Patents

Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Info

Publication number
PL442000A1
PL442000A1 PL442000A PL44200020A PL442000A1 PL 442000 A1 PL442000 A1 PL 442000A1 PL 442000 A PL442000 A PL 442000A PL 44200020 A PL44200020 A PL 44200020A PL 442000 A1 PL442000 A1 PL 442000A1
Authority
PL
Poland
Prior art keywords
colorectal cancer
blood
assessment
diagnostic test
early detection
Prior art date
Application number
PL442000A
Other languages
English (en)
Other versions
PL242924B1 (pl
Inventor
Jan LUBIŃSKI
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Katarzyna Białkowska
Anna Jakubowska
Wojciech MARCINIAK
Róża Derkacz
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL442000A priority Critical patent/PL242924B1/pl
Publication of PL442000A1 publication Critical patent/PL442000A1/pl
Publication of PL242924B1 publication Critical patent/PL242924B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nieoczekiwanie ustalono, że istnieje korelacja między stężeniem arsenu we krwi pełnej przy jednoczesnej ocenie genotypu GPX1 rs1050450 z bardzo wysoką częstością występowania raka jelita grubego u kobiet w populacji polskiej.
PL442000A 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów PL242924B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL442000A PL242924B1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442000A PL242924B1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Publications (2)

Publication Number Publication Date
PL442000A1 true PL442000A1 (pl) 2022-12-19
PL242924B1 PL242924B1 (pl) 2023-05-15

Family

ID=84487963

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442000A PL242924B1 (pl) 2020-05-14 2020-05-14 Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów

Country Status (1)

Country Link
PL (1) PL242924B1 (pl)

Also Published As

Publication number Publication date
PL242924B1 (pl) 2023-05-15

Similar Documents

Publication Publication Date Title
IL155312A0 (en) Apparatuses and methods for analyte concentration determination
Schneider et al. Sarcopenia and major complications in patients undergoing oncologic colon surgery
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
GB2440470A (en) Devices and methods for sample collection and analysis
Dadgar et al. Optical spectroscopic sensing of tumor hypoxia
DE602005017492D1 (de) Kombiniertes gerät zum messen von blutzucker aus augenflüssigkeit
ZA202005364B (en) A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
Huang et al. Is tumor size a predictor of preoperative N staging in T2–T4a stage advanced gastric cancer?
PL442000A1 (pl) Test diagnostyczny wczesnego wykrywania raków jelita grubego u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów
TN2022000166A1 (en) Adjustment method for adjusting a setup for an analytical method
PL442001A1 (pl) Test diagnostyczny wczesnego wykrywania raków piersi u kobiet oparty o ocenę stężeń arsenu we krwi i wybranych genotypów
JP2019011992A (ja) 卵内の検査装置
EA202090439A1 (ru) Способы и материалы для оценки и лечения рака
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
Seikkula et al. Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy
WO2025096779A3 (en) Methods of treatment with a myosin inhibitor using protein levels
RU2007119815A (ru) Способ выявления групп риска развития рецидива и метастазов рака молочной железы
Mroczko et al. Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue.
WO2019170545A8 (en) Means for the quantitative determination of an analyte concentration in a patient's urine sample
WO2021159128A3 (en) Methods and kit for detection of analytes
PL437895A1 (pl) Sposób określenia ryzyka raków u mężczyzn w zależności od stężenia miedzi we krwi
Goldberg et al. CAN FREE PSA BE USED AS A BIOMARKER IN BIOCHEMICAL RECURRENCE AFTER SURGERY TO PREDICT CASTRATE RESISTANT PROSTATE CANCER?: PD56-09
WO2024059841A3 (en) Analyte detection and quantification
PL441999A1 (pl) Sposób określenia ryzyka raków u mężczyzn w zależności od stosunku stężeń wybranych pierwiastków we krwi
Rock et al. Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi